Sigenome non targeting control

A375 crSOX10 knockout cells were transfected with either siGenome non-targeting control (Dharmacon, Lafayette, CO, #CTM-602672/APLAB-000061), siRNA targeting JUND (Dharmacon, Lafayette, CO, #D-003900-09, #D-003900-08) or siRNA targeting FOSL2 (Dharmacon, Lafayette, CO, #D-004110-01) at a final concentration of 25 nM using Lipofectamine RNAiMAX (Invitrogen, San Diego, CA, #56532). Sequences are as follows: JUND#9, GAAACACCCUUCUACGGCG; JUND#8, CGCUCAAGGACGAGCCACA; FOSL2#1, GGCCCAGUGUGCAAGAUUA; Non-targeting siGenome control, UAGCGACUAAACACAUCAAUU. MeWo and A375 parental and crSOX10 knockout cells were transfected with either on-target control siRNA (Dharmacon, Lafayette, CO, #D-001810-01) or siRNA targeting cIAP1 (Dharmacon, Lafayette, CO, #J-004390-12), and MeWo MTC, A375 CRT34 cells, and A375 CRT35 cells were transfected with either siGenome non-targeting control (Dharmacon, Lafayette, CO, #CTM-602672/APLAB-000061), siRNA targeting NFκB p50 (Dharmacon, Lafayette, CO, #D-003520-01), or siRNA targeting NFκB p65 (Cell Signaling, Danvers, MA, #6261) at a final concentration of 25 nM using Lipofectamine RNAiMAX (Invitrogen, San Diego, CA). Sequences are as follows: cIAP1, UCGCAAUGAUGAUGUCAAA; NFκB p50, GCAGGUAUUUGACAUAUUA; NFκB p65, the sequence is not publicly available; On-target control, UGGUUUACAUGUCGACUAAUU; Non-targeting siGenome control, UAGCGACUAAACACAUCAAUU.